Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Wants Chuikyo to Work Out Policies on Insurance Coverage for Infertility Treatments in Early 2022
December 16, 2020
- AMED’s Private Information on 1,400 Employees Might Be Leaked due to Unauthorized Access
December 16, 2020
- MHLW Urges Drug Makers to Boost Manufacturing Control after Itraconazole Issue
December 15, 2020
- No Plan to Investigate Efficacy of Japanese Encephalitis Vaccines against COVID-19: Govt
December 15, 2020
- Japan to Prioritize COVID-19 Vaccinations for Doctors, Staffers in Frequent Contact with Infected Patients
December 15, 2020
- Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
- Off-Year Re-Pricing Should Be Done in “Extremely Limited Scope” If Conducted: LDP Panel
December 14, 2020
- Ono’s Cancer Cachexia Med Clears PAFSC Review after Recommendation Hold
December 14, 2020
- Chuikyo Healthcare Rep Wants Off-Year Re-Pricing Threshold Set at 2 Times-Plus Average Price Gap, Payers Want Further Estimates for Larger Product Coverage
December 14, 2020
- Council OKs Public Knowledge-Based Applications for 4 Indications Including New Pediatric Dosage for Busulfex
December 14, 2020
- Ruling Parties Hammer Out Tax Reform Outline for FY2021
December 11, 2020
- MHLW Unveils Overview of COVID-19 Vaccine Distribution Scheme in Japan
December 11, 2020
- Fukui Pref. Govt Launches On-Site Inspection at Kobayashi Kako over Itraconazole Contaminated with Sleep Inducer
December 11, 2020
- Lyrica Faces Generic Debuts in Japan amid Patent Row: December Listing
December 10, 2020
- Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
- 2-Year Extension OK’ed for Raise on R&D Tax Credit Rates, Ceiling: LDP Subcommittee
December 9, 2020
- MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
- MHLW Ordered Label Revisions for 5 Drugs Including Alexion’s Soliris
December 9, 2020
- Adrenomedullin, Baricitinib Added to MHLW’s COVID-19 Guide
December 8, 2020
- MHLW Panel OKs Takeda’s ALK Drug, Lynparza’s Pancreatic Cancer Use; Seikagaku’s Osteoarthritis Med Put under Continued Review
December 7, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…